Cat. No. 1409
Chemical Name: (E)-(±)-2-Amino-4-methyl-5-phosphono
Biological ActivityPotent, selective and competitive NMDA antagonist (Ki = 310 nM for inhibition of [3H]-CPP binding in rat brain). Centrally active upon oral administration in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
D'Hooge et al (1999) Effects of competitive NMDA receptor antagonists on excitatory amino-acid-evoked currents in mouse spinal cord. Fundam.Clin.Pharmacol. 13 67. PMID: 10027090.
Loscher and Honack (1991) Anticonvulsant and behavioural effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J.Pharmacol.Exp.Ther. 256 432. PMID: 1671593.
Fagg et al (1990) CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-asparate receptor antagonists with oral activity. Br.J.Pharmacol. 99 791. PMID: 1972895.
If you know of a relevant reference for CGP 39551 please let us know.
Citations are publications that use Tocris products. Selected citations for CGP 39551 include:
Grieder et al (2012) Phasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal. Proc Natl Acad Sci U S A 109 3101. PMID: 22308372.
Bäckström and Hyytiä (2006) Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 31 778. PMID: 16123768.
Do you know of a great paper that uses CGP 39551 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: CGP 39551, supplier, Potent, selective, competitive, NMDA, antagonist, Glutamate, Receptors, N-Methyl-D-Aspartate, iGlur, Ionotropic, CGP39551, Tocris Bioscience, NMDA Receptor Antagonist products